Age as a determinant of sensitivity to warfarin.

Shepherd, Alexander M; Hewick, D S; Moreland, T. A.; Stevenson, I. H.

doi:10.1111/j.1365-2125.1977.tb00719.x

Cited by 243 publications

(89 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The phenomenon is not universal, however. Warfarin binding in plasma does not fall in the elderly, for example (Shepherd et al, 1977;Routledge et al, 1979).…”

Section: Introductionmentioning

confidence: 99%

The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.

Davis¹,

Sh²,

Kitchell³

et al. 1985

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…The phenomenon is not universal, however. Warfarin binding in plasma does not fall in the elderly, for example (Shepherd et al, 1977;Routledge et al, 1979).…”

Section: Introductionmentioning

confidence: 99%

The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.

Davis¹,

Sh²,

Kitchell³

et al. 1985

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…For some of them, for example age, the direction and the degree with which they interfere with the effects of oral anticoagulants has been determined with some precision (O'Malley et al, 1977;Husted & Andreasen, 1977;Shepherd et al, 1977;Routledge et al, 1979). Other factors such as sex and indication for treatment remain controversial and uncertain (O'Malley et al, 1977;Routledge et al, 1979;Arboix et al, 1984).…”

Section: Discussionmentioning

confidence: 99%

The potentiation of acenocoumarol anticoagulant effect by amiodarone.

Arboix¹,

Frati²,

Laporte³

1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

I Out of 690 patients (337 males and 353 females) on long-term acenocoumarol therapy, 80 (35 males and 45 females) were taking amiodarone. Forty patients had started amiodarone treatment while being treated with acenocoumarol. Of these, nine patients had begun amiodarone treatment while taking acenocoumarol. 2 The relation between the daily dose of acenocoumarol and the prothrombin ratio (AC dose/PR ratio) has been considered a useful indicator to study the interaction between amiodarone and acenocoumarol. 3 Differences of acenocoumarol daily dose between takers and non-takers of amiodarone were statistically significant (t = 5.35; P < 0.001) for the whole population, for all the age groups, and also among males (t = 2.43; P < 0.01) as well as among females (t =5.38;P<0.001). 4 Out of 40 patients chronically treated with acenocoumarol in whom amiodarone was instituted, 32 showed a decrease of the AC dose/PR ratio, while in eight patients no change was recorded (paired t-test, t = 5.82; P < 0.001). 5In 15 patients who were being concomitantly treated with acenocoumarol and amiodarone, amiodarone was discontinued. An increase of the AC dose/PR ratio was recorded (paired t-test, t = 4.01; P < 0.001). 6 Nine patients had started treatment with amiodarone while receiving acenocoumarol and a decrease of the AC dose/PR ratio was documented; amiodarone was discontinued some months later, and an increase of the AC dose/PR ratio was seen.

show abstract

“…Shepherd, Hewick, Moreland & Stevenson (1977) showed that vitamin K dependent clotting factors were more effectively inhibited by warfarin in the elderly. Clotting factor degradation, however, did not change with age, neither did the pharmacokinetics of warfarin.…”

Section: Methodsmentioning

confidence: 99%

Comparison of a new microcrystalline dicoumarol preparation with warfarin under routine treatment conditions.

Lockner¹,

Paul²

1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 To determine whether two different oral anticoagulants show difference under routine clinical conditions, 71 patients were randomized to treatment with Apekumarol, a microcrystalline dicoumarol preparation, and 72 patients to treatment with warfarin. 2 During the inpatient phase of treatment both drug groups remained for about 94% of their treatment time within prothrombin value limits of 5‐25% (Simplastin A). No statistically significant difference was found between the drugs. 3 While under outpatient care, both drug groups remained for about 80% of their treatment time within prothrombin value limits of 5‐25%. No statistically significant difference was found between the drugs. 4 The intensity of control and number of prothrombin‐ determinations did not differ significantly between the groups. 5 Variations in the daily dose did not differ significantly between the groups. 6 The mean daily dose could not be correlated to mean body weight. 7 The mean daily dose decreased with age for the male patients taking warfarin, not for the female patients. There was no such decrease for either male or female patients taking Apekumarol. An additional 137 patients who at the time of the trial were under routine treatment with warfarin were also studied with regard to mean daily dose, age and sex. In this additional group the mean daily dose could be correlated with age in both males and females. 8 No difference between Apekumarol and warfarin could be demonstrated when tested under routine clinical conditions according to the design of the present study. Sensitivity for warfarin, but not for Apekumarol, seems to increase with age, this sensitivity has been demonstrated in both sexes.

show abstract

Age as a determinant of sensitivity to warfarin.

Cited by 243 publications

References 20 publications

The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.

The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.

The potentiation of acenocoumarol anticoagulant effect by amiodarone.

Comparison of a new microcrystalline dicoumarol preparation with warfarin under routine treatment conditions.

Contact Info

Product

Resources

About